PTIX Stock Overview
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Protagenic Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.57 |
| 52 Week High | US$2.32 |
| 52 Week Low | US$0.68 |
| Beta | 0.38 |
| 1 Month Change | -9.86% |
| 3 Month Change | 74.29% |
| 1 Year Change | -14.21% |
| 3 Year Change | -82.48% |
| 5 Year Change | -80.38% |
| Change since IPO | -97.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| PTIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.3% | 1.5% | 1.2% |
| 1Y | -14.2% | 1.1% | 24.7% |
Return vs Industry: PTIX underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: PTIX underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PTIX volatility | |
|---|---|
| PTIX Average Weekly Movement | 17.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PTIX's share price has been volatile over the past 3 months.
Volatility Over Time: PTIX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2 | n/a | www.protagenic.com |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company’s lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Protagenic Therapeutics, Inc. Fundamentals Summary
| PTIX fundamental statistics | |
|---|---|
| Market cap | US$6.96m |
| Earnings (TTM) | -US$5.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs PTIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTIX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.00m |
| Earnings | -US$5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PTIX perform over the long term?
See historical performance and comparison